PET imaging has shown its value in diagnosing diseases affecting older people. Most significantly this has been with regard to the diagnosis of Alzheimer’s disease and other forms of dementia. Parkinson’s disease is another condition in which PET has proved valuable. This issue also included articles on the uses of PET for diagnosing cerebrovascular disease and for assessing neuroplasticity.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. PET Clinics - p. 5 6. CME Accreditation Page and Author Disclosure - p. 6 7. Preface - p. 7 8. Normal Patterns and Variants in PET Brain Imaging - p. 8 9. Evaluation of Early Dementia (Mild Cognitive Impairment) - p. 18 10. Amyloid PET Ligands for Dementia - p. 29 11. 18F-Fluorodeoxyglucose PET in the Evaluation of Parkinson Disease - p. 46 12. SPECT and PET in Atypical Parkinsonism - p. 53 13. 18F-AV-133: A Selective VMAT2-binding Radiopharmaceutical for PET Imaging of Dopaminergic Neurons - p. 61 14. PET in Cerebrovascular Disease - p. 67 15. Imaging Pathophysiology and Neuroplasticity After Stroke - p. 86 16. Index - p. 99
PET imaging has shown its value in diagnosing diseases affecting older people. Most significantly this has been with regard to the diagnosis of Alzheimer’s disease and other forms of dementia. Parkinson’s disease is another condition in which PET has proved valuable. This issue also included articles on the uses of PET for diagnosing cerebrovascular disease and for assessing neuroplasticity.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. PET Clinics - p. 5 6. CME Accreditation Page and Author Disclosure - p. 6 7. Preface - p. 7 8. Normal Patterns and Variants in PET Brain Imaging - p. 8 9. Evaluation of Early Dementia (Mild Cognitive Impairment) - p. 18 10. Amyloid PET Ligands for Dementia - p. 29 11. 18F-Fluorodeoxyglucose PET in the Evaluation of Parkinson Disease - p. 46 12. SPECT and PET in Atypical Parkinsonism - p. 53 13. 18F-AV-133: A Selective VMAT2-binding Radiopharmaceutical for PET Imaging of Dopaminergic Neurons - p. 61 14. PET in Cerebrovascular Disease - p. 67 15. Imaging Pathophysiology and Neuroplasticity After Stroke - p. 86 16. Index - p. 99
